Stay updated on BGB324 with Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the BGB324 with Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the BGB324 with Pembrolizumab in Melanoma Clinical Trial page
- Check7 days agoChange DetectedMelanoma and MedlinePlus Genetics were removed from the related topics section on the page.SummaryDifference0.2%

- Check14 days agoChange DetectedThe page updated to Revision: v3.4.2 and removed the prior notices including the lapsed funding notice and Revision: v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check21 days agoChange DetectedSite-wide notice about government funding and NIH operating status was added, and the page version was updated from 3.4.0 to 3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check28 days agoChange DetectedThe page adds a glossary display and related topics (Melanoma and MedlinePlus Genetics). Revision information is updated to v3.4.0 and older entries (Last Update Submitted that met QC Criteria, No FEAR Act data, Revision: v3.3.4) are removed; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check35 days agoChange DetectedMelanoma and MedlinePlus Genetics terms were deleted from the page's topic areas. This reduces disease-specific descriptors and related resources on the study record.SummaryDifference0.2%

- Check42 days agoChange DetectedMinor revision update; the page version changed from v3.3.3 to v3.3.4 with no substantive content changes detected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to BGB324 with Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BGB324 with Pembrolizumab in Melanoma Clinical Trial page.